Literature DB >> 3881910

Calcium-entry blockers, vascular smooth muscle and systemic hypertension.

P M Vanhoutte.   

Abstract

Abnormal narrowing of the arterioles, caused by contraction of arteriolar smooth muscle, contributes to the genesis and the maintenance of the increased peripheral resistance observed in hypertension. Activation of the contractile process in vascular smooth muscle requires an increase in cytoplasmic calcium. In most blood vessels, the activator ion enters the cell through specific membrane channels, which can be inhibited by a chemically heterogeneous group of drugs, the calcium-entry blockers. The antihypertensive effect of these agents is probably explained by their inhibitory effect on (1) alpha-adrenergic activation (the pharmacologic subtype of postjunctional alpha-adrenoceptor does not necessarily determine the importance of calcium entry); (2) activation by nonadrenergic neurohumoral mediators (for example, serotonin); (3) acceleration of calcium entry by metabolites of arachidonic acid formed by lipoxygenase; and (4) inherent myogenic tone.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3881910     DOI: 10.1016/0002-9149(85)90609-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Effect of calcium entry blockers on blood pressure and vasoconstrictor responses to alpha-1 adrenoceptor stimulation in conscious spontaneously hypertensive rats.

Authors:  M J Thoolen; C R Miller; A T Chiu; P B Timmermans
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

Review 2.  Why are converting enzyme inhibitors vasodilators?

Authors:  P M Vanhoutte; W Auch-Schwelk; M L Biondi; R R Lorenz; V B Schini; M J Vidal
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

3.  Correlation of blood pressure in end-stage renal disease with platelet cytosolic free-calcium concentration.

Authors:  H Schiffl
Journal:  Klin Wochenschr       Date:  1990-07-17

Review 4.  Brain protection: physiological and pharmacological considerations. Part I: The physiology of brain injury.

Authors:  J Murdoch; R Hall
Journal:  Can J Anaesth       Date:  1990-09       Impact factor: 5.063

Review 5.  Pharmacological management of hypertension in paediatric patients. A comprehensive review of the efficacy, safety and dosage guidelines of the available agents.

Authors:  K Miller
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

6.  c-Jun NH₂-terminal kinase contributes to dexmedetomidine-induced contraction in isolated rat aortic smooth muscle.

Authors:  Seong-Ho Ok; Young Seok Jeong; Jae-Gak Kim; Seung-Min Lee; Hui-Jin Sung; Hye Jung Kim; Ki Churl Chang; Seong-Chun Kwon; Ju-Tae Sohn
Journal:  Yonsei Med J       Date:  2011-05       Impact factor: 2.759

7.  Heme oxygenase-1 regulates cell proliferation via carbon monoxide-mediated inhibition of T-type Ca2+ channels.

Authors:  Hayley Duckles; Hannah E Boycott; Moza M Al-Owais; Jacobo Elies; Emily Johnson; Mark L Dallas; Karen E Porter; Francesca Giuntini; John P Boyle; Jason L Scragg; Chris Peers
Journal:  Pflugers Arch       Date:  2014-04-18       Impact factor: 3.657

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.